Agreement with Ivoclar Vivadent Limited for the supply of sterilisation packaging products and associated consumables
PHARMAC is pleased to announce the approval of an agreement with Ivoclar Vivadent Limited (“Ivoclar Vivadent”) for the supply of sterilisation packaging products and associated consumables.
This was the subject of a consultation letter dated 15 July 2016 which can be found on PHARMAC’s website.
In summary, the effect of the decision is that:
- A range of 7 sterilisation pouches will be listed in Section H, Part III, (‘Optional Pharmaceuticals’) of the Pharmaceutical Schedule from 1 September 2016.
- DHB hospitals can purchase these items either directly from Ivoclar Vivadent or through a designated third party logistics provider under the national agreement.
Details of the decision
Following a two stage process for national contracting, an Expression of Interest (EOI) issued in July 2015 and a closed Request for Proposals (RFP) in October 2015, PHARMAC has entered into an agreement with Ivoclar Vivadent Limited for the supply of a selection of sterilisation packaging products and associated consumables to be listed on the Pharmaceutical Schedule. This means that DHB hospitals that purchase these products must do so under the national agreement at the new pricing from 1 September 2016.
The list of products will be available, as of 1 September 2016 on PHARMAC’s website, in both a PDF document and a series of Excel spreadsheets.
Ivoclar Vivadent is an incumbent supplier of sterilisation packaging products and associated consumables to DHBs and the agreement offers a small savings to DHBs, based on current usage.
This agreement is not exclusive. DHBs can continue to purchase other brands of sterilisation packaging products and associated consumables at their discretion.
Educational services will be provided by Ivoclar Vivadent on the appropriate use of their sterilisation packaging products and associated consumables and this will be arranged in a format and at times agreed with individual DHBs.
PHARMAC appreciates all of the feedback that it has received and acknowledges the time people took to respond. All consultation responses received by 5 August 2016 were considered in their entirety in making a decision on the proposed changes. No concerns were raised regarding the proposals.
If you have any questions about this decision you can email PHARMAC at email@example.com or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.